Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
titanocene dichloride
- Development stage
- Discontinued
- Lead developer
- medac
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Titanocene dichloride is an organotitanium compound with the formula (η^5-C5H5)2TiCl2, commonly abbreviated as Cp2TiCl2. It is a red to red-orange crystalline solid that slowly hydrolyzes in air and decomposes in water. Titanocene dichloride was the first non-platinum coordination complex and the first metallocene to undergo clinical trials as an anticancer agent. Its mechanism of action differs from platinum-based drugs like cisplatin; while cisplatin binds preferentially to DNA bases (N7 of guanine), titanocene dichloride exhibits higher affinity for the phosphate backbone of DNA and can also bind transferrin after hydrolysis in aqueous environments. It has shown activity against cisplatin-resistant cancer cells in vitro and was investigated primarily for its antitumor properties but development was discontinued after phase 2 trials[4][5][6][7]. Besides its experimental use as a chemotherapeutic agent, it is widely used as a reagent in organometallic chemistry and organic synthesis.
- Other names
- bis(cyclopentadienyl)titanium dichlorideCp2TiCl2Cp-2TiCl2Cp 2TiCl2titanocene
02
Targets
DNA
Beyond the preview
Go deeper on titanocene dichloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on titanocene dichloride.